CAPR · Pre-market
$8.68
-7.13% today·exchange $8.68
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative cell- and exosome-based therapies, primarily targeting Duchenne muscular dystrophy (DMD).
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
Simply Wall St. · 21h ago
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
GlobeNewswire · 7d ago
Sector Update: Healthcare Stocks Gain Late Afternoon
MT Newswires · 10d ago
Capricor Therapeutics Shares Rise After Upgrade From B. Riley
MT Newswires · 10d ago
B. Riley Upgrades Capricor Therapeutics to Buy From Neutral, Raises Price Target to $21 From $5
MT Newswires · 10d ago
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
MarketBeat · 11d ago
Headlines from Yahoo Finance. Not investment advice.
